MedTrace Logo

Transcranial Doppler Ultrasound and Minimal Hepatic Encephalopathy

NCT04077125 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2019-09-04

No results posted yet for this study

Summary

Minimal hepatic encephalopathy (MHE) is a subclinical complication of liver cirrhosis with a relevant social impact. Thus, there is urgent need to implement easy to use diagnostic tools for the early identification of affected patients.

This study was aimed to investigate cerebral blood flow, systemic hemodynamics as well as endothelial function of cirrhotic patients with MHE, and to verify their change after treatment with rifaximin.

Conditions

  • Minimal Hepatic Encephalopathy

Interventions

DRUG

Rifaximin

to investigate changes in cerebral, splanchnic hemodynamics and endothelial function in cirrhotic patients with MHE after 15 days of rifaximin therapy (1200 mg/d)

Sponsors & Collaborators

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-18
Primary Completion
2018-12-31
Completion
2019-03-01

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04077125 on ClinicalTrials.gov